| Packaging Type | Vial |
| Country of Origin | Made in India |
| Brand Name | Zytorvi |
| Salt Composition | Toripalimab 240mg |
| Manufacturer | DR REDDY'S LABORATORIES LTD |
Zytorvi 240mg Injection contains the active ingredient Toripalimab. It is a monoclonal antibody used in the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC). It is administered as a first-line therapy in combination with cisplatin and gemcitabine for adult patients and as a single agent for those with recurrent, unresectable, or metastatic NPC that has progressed after platinum-based chemotherapy.
Zytorvi 240mg Injection works by blocking the PD-1 receptor, preventing its interaction with the PD-L1 and PD-L2 ligands. This action lifts the inhibition on T cells, boosting their activity and enhancing immune surveillance, ultimately promoting an anti-tumor immune response. In preclinical models, PD-1 blockade demonstrated a reduction in tumor growth.
Zytorvi 240mg Injection is associated with common side effects, including nausea and vomiting, burning or tingling sensations in the feet and toes, decreased appetite, diarrhea, and constipation. It carries warnings for severe immune-mediated adverse reactions, which may affect any organ or tissue and could be fatal. These reactions can occur at any time during treatment or even after discontinuation, requiring close monitoring and immediate medical intervention when necessary.
Also, infusion-related reactions such as hypersensitivity and anaphylaxis may occur during administration. For patients who have undergone or are undergoing allogeneic hematopoietic stem cell transplantation (HSCT), Zytorvi 240mg Injection may lead to serious complications such as graft-versus-host disease (GVHD) and other transplant-related issues. Zytorvi 240mg Injection is contraindicated during pregnancy due to the risk of fetal harm, including potential fetal death.
Uses
First-line treatment for adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) in combination with cisplatin and gemcitabine.Single-agent treatment for adults with recurrent, unresectable, or metastatic NPC that has progressed after platinum-containing chemotherapy.
Storage
Store in the original packaging to protect from moisture.Avoid direct sunlightStore Zytorvi 240mg Injection in a refrigerator at a temperature of 2°C to 8°C.Do not freeze or shake it.
Side Effects
Decreased appetiteNausea and vomitingConstipation and diarrhoeaMuscle and bone painDizzinessBurning or feeling of pins and needles in feet and toesUpper respiratory infectionSleep problemsRashFever and coughLow levels of thyroid hormoneSevere allergic reactions such as difficulty breathing, swelling of face or throatLiver problems (e.g., yellowing of skin or eyes, dark urine)Lung problems (e.g., shortness of breath, cough, chest pain)Immune system problems leading to inflammation in organsEndocrine problemsSevere infections